搜尋結果
Eisai's Drug Discovery, Research and Development Sites Worldwide. Flow of R&D (Drug Creation Research) Latest Major R&D Pipeline. Key Therapeutic Areas. Clinical Trials. Use of Digital Technology. Policies and Guidelines.
2009年4月28日 · With the approval of Zebinix®, Eisai Europe will launch Zebinix® during FY2009 and FY2010 across Europe, under the terms of a license and co-promotion agreement signed with Bial on February 19 th this year. Eisai has been selling two other anti-epileptic drugs, Zonegran® for partial-onset seizures and Inovelon® for Lennox-Gastaut Syndrome ...
- Zebinix®
- Tablet
- April 21st, 2009
- eslicarbazepine acetate
- hk.tv.yahoo.com
2024年6月3日 · Eisai Announces Appointments of Directors and Corporate Officers. June 10, 2024. FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease. June 3, 2024.
Eisai is working on improving access to medicines, especially in developing and emerging countries, with the aim of making our medicines available to those who need them regardless of healthcare system and income level in each country.
2019年5月16日 · The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor α covalent antagonist), which were discovered by Eisai’s U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO.
An introduction to Targets and Results. ESG Data and Independent Assurance. Social responsibility index and ESG (Environmental, Social, Governance) index for stakeholders to make a comprehensive assessment of corporate activities from an objective viewpoint in addition to an independent assurance. GRI Content Index.
2024年4月24日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI ® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the ...
